by Tony Akiwumi | Nov 19, 2025 | Pharma / Market Access
In 2017, a major global bank spent nearly £300 million developing a digital platform that it eventually scrapped. The reason? No one had the courage to stop it earlier. Everyone feared appearing negative. Leadership meetings became exercises in optimism rather than...
by Tony Akiwumi | Nov 19, 2025 | Pharma / Market Access
When athletes train for the Olympics, they receive constant feedback — not once a year, but every session. Yet in corporate life, feedback often arrives too late to make a difference. Performance reviews become rituals rather than instruments of growth. Feedback is...
by Tony Akiwumi | Nov 19, 2025 | Pharma / Market Access
When the Concorde first took flight, it symbolised bold innovation. It was beautiful, fast, and technologically unmatched. Yet, it failed commercially because the strategic balance between creativity and risk was never resolved. It was an engineering triumph but a...
by Tony Akiwumi | Nov 18, 2025 | Pharma / Market Access
A few years ago, two pharmaceutical companies released similar treatments within months of each other. Both had comparable science and funding. Yet one became a global success while the other vanished quietly. The difference was not in their laboratories but in their...
by Tony Akiwumi | Nov 18, 2025 | Pharma / Market Access
When the London Underground introduced the Oyster Card, resistance was fierce. Staff feared redundancy, commuters distrusted technology, and the press predicted chaos. Yet within a few years it became one of the most successful transport innovations in the world. The...
by Tony Akiwumi | Nov 18, 2025 | Pharma / Market Access
In 1961, President John F. Kennedy stood before Congress and declared that America would land a man on the moon before the decade was out. It was a vision both absurd and electrifying. It was also clear. Everyone understood what success looked like. Contrast that with...
